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Background: Most HIV-1 transmissions occur via genitorectal 
mucosa, highlighting the need for vaccines that elicit mucosal 
immunity. HIV Gag-specific cell mediated immunity (CMI) and 
anti-Tat neutralizing antibodies are considered essential for long-
term control of HIV. Thus, Gag and Tat are desirable components 
of a HIV vaccine. We developed a candidate mucosal vaccine by 
engineering a replication-competent human rhinovirus serotype 
A1 (HRV-A1) to encode Gag and Tat (rHRV-Gag/Tat). Intranasal 
administration of this novel vaccine may generate robust pan-
mucosal and systemic HIV-specific immunity. 
Methods: Balb/c mice (n=7 per group) were vaccinated 
intranasally with 2 doses (5x106 TCID50/dose) of rHRV-Gag/Tat ( 
referred to hereafter as rHRV-DNA vaccination) or WT-HRV then 
boosted intradermally with a 50 µg of a DNA vaccine encoding 
Gag and a novel oligomerised Tat (pVAXGag/Tat). Another group 
of mice received 3 intradermal doses (50 µg/dose) of pVAXGag/
Tat ( referred to hereafter as pVAXGag/Tat vaccination). 
Splenocytes and lymphocytes from mesenteric lymph nodes 
were analysed for Gag-specific systemic and mucosal CMI by 
ELIspot and ICS. We also analysed blood and cervical vaginal 
lavage (CVL) samples for Tat-specific systemic (IgG) and 
mucosal (IgA), respectively. 
Results: rHRV-DNA vaccination elicited superior multi-
functional CD8+T cell responses in lymphocytes harvested from 
mesenteric lymph nodes and spleens, and higher titres of Tat-
specific antibodies in blood and vaginal lavages, and reduced 
the viral load more effectively after challenge with EcoHIV, 
a murine HIV challenge model, in peritoneal macrophages, 
splenocytes and blood compared compared with wt-HRV-A1/
pVAX vaccination or administration of 3 ID doses of pVAX-Gag-
Tat (3X pVAX-Gag-Tat vaccination). 
Conclusions: Data shows that rHRV-DNA vaccination can induce 
HIV-specific immune responses in the gut, vaginal mucosa and 
systemically, and supports further testing of this regimen in the 
development of an effective mucosally-targeted HIV-1 vaccine.
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Background: To be effective against HIV-1, vaccine-induced 
T cells must selectively target functionally conserved and, at 
the same time, protective epitopes present on the majority of 
currently circulating and reactivated HIV-1 strains, and rapidly 
reach protective frequencies upon exposure to the virus. 
Heterologous prime-boost regimens using virally vectored 
vaccines are currently the most promising strategy towards 
achieving this goal, nevertheless, induction of robust long-
term memory remains challenging. To this end, lentiviral 
vectors induce high frequencies of memory cells due to their 
low-inflammatory nature, while typically inducing only low anti-
vector immune responses. 
Methods: We describe construction of novel candidate vaccines 
ZVex.tHIVconsv1 and ZVex.tHIVconsv2, which are based on an 
integration-deficient lentiviral vector platform with preferential 
transduction of human dendritic cells and express bivalent 
mosaic of conserved-region T-cell immunogens with a high 
global HIV-1 match. 
Results: Each of the two mosaics was individually immunogenic 
and together in heterologous prime-boost regimens with non-
replicating simian (chimpanzee) adenovirus or non-replicating 
poxvirus MVA vaccines induced very high frequencies of 
plurifunctional and broadly cross-reactive T cells in BALB/c and 
outbred CD1-SWISS mice. 
Conclusions: These data support further development of this 
vaccine concept.
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